Rilpivirine is a pharmaceutical drug, developed by Tibotec, for the treatment of HIV infection. It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs, such as efavirenz. Rilpivirine entered phase III clinical trials in April 2008, and was approved for use in the United States in May 2011. A fixed-dose drug combining rilpivirine with emtricitabine and tenofovir, was approved by the U.S. Food and Drug Administration in August 2011 under the brand name Complera.
Properties:
Density: 1.27g/cm3
Boiling Point: 634.1ºC at 760 mmHg
Melting Point: 245ºC
Flash Point: 337.3ºC
Refractive Index: 1.665
Reverse Transcriptase Inhibitors Related Prodcuts:
Tenofovir alafenamide fumarate; Tenofovir alafenamide; Alovudine; Adefovir; Adefovir dipivoxil; Abacavir; Abacavir sulfate; Efavirenz; Lersivirine